SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Up 64.4% in February

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 61,800 shares, an increase of 64.4% from the February 13th total of 37,600 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 74,500 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SOPH. Dimensional Fund Advisors LP increased its position in shares of SOPHiA GENETICS by 23.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company's stock worth $68,000 after purchasing an additional 4,115 shares in the last quarter. Silverberg Bernstein Capital Management LLC bought a new stake in SOPHiA GENETICS during the fourth quarter worth about $70,000. Green Alpha Advisors LLC grew its stake in SOPHiA GENETICS by 119.3% during the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company's stock worth $145,000 after buying an additional 25,686 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of SOPHiA GENETICS by 40.5% during the fourth quarter. Federated Hermes Inc. now owns 100,000 shares of the company's stock worth $312,000 after buying an additional 28,819 shares in the last quarter. Finally, Millennium Management LLC raised its stake in shares of SOPHiA GENETICS by 6.5% in the fourth quarter. Millennium Management LLC now owns 698,634 shares of the company's stock valued at $2,180,000 after acquiring an additional 42,689 shares during the last quarter. 31.59% of the stock is owned by institutional investors.

Remove Ads

SOPHiA GENETICS Price Performance

Shares of SOPHiA GENETICS stock traded down $0.21 during trading on Wednesday, hitting $3.00. 38,239 shares of the company's stock traded hands, compared to its average volume of 69,430. The company has a market cap of $200.06 million, a PE ratio of -2.75 and a beta of 1.01. The firm's fifty day moving average price is $3.58 and its 200 day moving average price is $3.53. SOPHiA GENETICS has a twelve month low of $2.70 and a twelve month high of $6.28. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last issued its earnings results on Tuesday, March 4th. The company reported ($0.23) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.23). The business had revenue of $17.73 million during the quarter, compared to analysts' expectations of $17.71 million. SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. Analysts forecast that SOPHiA GENETICS will post -0.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SOPH. Craig Hallum started coverage on shares of SOPHiA GENETICS in a research note on Wednesday, December 18th. They issued a "buy" rating and a $11.00 target price for the company. BTIG Research set a $5.00 price objective on SOPHiA GENETICS in a research report on Thursday, March 6th.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.